TY - JOUR
T1 - The Association Between Novel Biomarkers and 1-Year Readmission or Mortality After Cardiac Surgery
AU - Jacobs, Jeffrey P.
AU - Alam, Shama S.
AU - Owens, Sherry L.
AU - Parker, Devin M.
AU - Rezaee, Michael
AU - Likosky, Donald S.
AU - Shahian, David M.
AU - Jacobs, Marshall L.
AU - Thiessen-Philbrook, Heather
AU - Wyler von Ballmoos, Moritz
AU - Lobdell, Kevin
AU - MacKenzie, Todd
AU - Everett, Allen D.
AU - Parikh, Chirag R.
AU - Brown, Jeremiah R.
N1 - Publisher Copyright:
© 2018 The Society of Thoracic Surgeons
PY - 2018/10
Y1 - 2018/10
N2 - Background: Novel cardiac biomarkers including soluble suppression of tumorigenicity 2, galectin-3, and the N-terminal prohormone of brain natriuretic peptide may be associated with long-term adverse outcomes after cardiac surgery. We sought to measure the association between cardiac biomarker levels and 1-year hospital readmission or mortality. Methods: Plasma biomarkers from 1,047 patients discharged alive after isolated coronary artery bypass graft surgery from 8 medical centers were measured in a cohort from the Northern New England Cardiovascular Disease Study Group between 2004 and 2007. We evaluated the association between preoperative and postoperative biomarkers and 1-year readmission or mortality using Kaplan-Meier estimates and Cox proportional hazards modeling, adjusting for covariates used in The Society of Thoracic Surgeons 30-day readmission model. Results: The median follow-up time was 365 days. After adjustment for established risk factors, above-median levels of postoperative galectin-3 (median 10.35 ng/mL; hazard ratio, 1.40; 95% confidence interval, 1.08 to 1.80; p = 0.010) and N-terminal prohormone of brain natriuretic peptide (median = 15.21 ng/mL, hazard ratio, 1.42; 95% confidence interval, 1.07 to 1.87; p = 0.014) were each significantly associated with 1-year readmission or mortality. Conclusions: In patients undergoing cardiac surgery, novel cardiac biomarkers were associated with readmission or mortality independent of established risk factors. Measurement of these biomarkers may improve our ability to identify patients at highest risk for readmission or mortality before discharge. This will also allow resource allocation accordingly, while implementing strategies for personalized medicine based on the biomarker profile of the patient.
AB - Background: Novel cardiac biomarkers including soluble suppression of tumorigenicity 2, galectin-3, and the N-terminal prohormone of brain natriuretic peptide may be associated with long-term adverse outcomes after cardiac surgery. We sought to measure the association between cardiac biomarker levels and 1-year hospital readmission or mortality. Methods: Plasma biomarkers from 1,047 patients discharged alive after isolated coronary artery bypass graft surgery from 8 medical centers were measured in a cohort from the Northern New England Cardiovascular Disease Study Group between 2004 and 2007. We evaluated the association between preoperative and postoperative biomarkers and 1-year readmission or mortality using Kaplan-Meier estimates and Cox proportional hazards modeling, adjusting for covariates used in The Society of Thoracic Surgeons 30-day readmission model. Results: The median follow-up time was 365 days. After adjustment for established risk factors, above-median levels of postoperative galectin-3 (median 10.35 ng/mL; hazard ratio, 1.40; 95% confidence interval, 1.08 to 1.80; p = 0.010) and N-terminal prohormone of brain natriuretic peptide (median = 15.21 ng/mL, hazard ratio, 1.42; 95% confidence interval, 1.07 to 1.87; p = 0.014) were each significantly associated with 1-year readmission or mortality. Conclusions: In patients undergoing cardiac surgery, novel cardiac biomarkers were associated with readmission or mortality independent of established risk factors. Measurement of these biomarkers may improve our ability to identify patients at highest risk for readmission or mortality before discharge. This will also allow resource allocation accordingly, while implementing strategies for personalized medicine based on the biomarker profile of the patient.
UR - http://www.scopus.com/inward/record.url?scp=85053457845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053457845&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2018.04.084
DO - 10.1016/j.athoracsur.2018.04.084
M3 - Article
C2 - 29864407
AN - SCOPUS:85053457845
SN - 0003-4975
VL - 106
SP - 1122
EP - 1128
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 4
ER -